Inclusion Criteria:  Aged 18 to 70 years HIV-1 infection by confirmed test; Receiving antiviral treatment ≥ 1 years; Current CD4+ T cell count > 350 cells/μl; HIV-1 RNA levels of < 50 copies/ml for at least a year; Patients who agrees to use two effective methods of contraception to avoid pregnancy during the study period. Patients who sign the informed consent form prior to inclusion in the study.  Exclusion Criteria:  Patients with concomitant HAV, HBV, HCV, HDV, HEV, EBV, CMV or syphilis infection; A history of AIDS-related opportunistic infections and tumors within 1 year prior to enrollment; A History of corticosteroids or immunosuppressive drugs for autoimmune diseases by physicians within the last 2 years;  Participants with clinically significant laboratory abnormalities as follows:  Hemoglobin ≤ 10 gm/dl (female), <11g/dl (male) Absolute neutrophil count ≤ 1×10^9/L Platelet count ≤100×10^9/L Alanine aminotransferase (ALT)≥ 2.5 x ULN Aspartate aminotransferase (AST) ≥ 2.5 x ULN Total bilirubin > 1.5 ULN Serum creatinine >110 μmol/L International normalized ratio (INR) >1.5 or activated partial thromboplastin time (APTT) >45 s Patients with severe psychiatric illness, drugs or alcohol abuse; A woman who is in pregnancy or lactation; A history of central nervous system disease, such as cerebral hemorrhage, dementia, epilepsy and autoimmune diseases; Patients with a non-AIDS-related serious underlying disease; Patients who participate in another clinical study currently which may affect the results of this study.